Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

158.38 +3.72 (+2.41%)
Official Closing Price Updated: 4:10 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Johnson & Johnson Gets Analyst Upgrade Noting Bullish Pharma & MedTech Projections
UBS has upgraded Johnson & Johnson (NYSE: JNJ), citing a bullish view of the company's pharmaceutical business and expectations for MedTech growth that align with the market, which is... 
Via Benzinga
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepresented the efficacy of its widely- 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Investors Should Not Pay More Than A 15 P/E Ratio When Buying A Stock
A look at how the P/E ratio can help determine if a stock is trading at a fair valuation or not, and whether it is a good investment. 
Via Talk Markets
Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio
Faced with a possible negative outcome in the market, these top healthcare stocks should offer the confidence you need. 
Via InvestorPlace
Warren Buffett Reduced This Long-Time Berkshire Hathaway Holding by 67%. Should Investors Follow His Lead?
Berkshire Hathaway trimmed several longtime holdings in the third quarter, including this stock it has held since 2001. 
Via The Motley Fool
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
Is NYSE:JNJ suited for dividend investing?
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19 
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
From Johnson & Johnson
Via Business Wire
7 Blue-Chip Stocks to Buy for 2024, According to AI
Technical indicators can predict stock prices when paired with fundamental analysis. Here's MarketMasterAI's latest blue chip stock picks. 
Via InvestorPlace
Income Kings: 7 Blue-Chip Dividend Stocks for Reliable Returns
Are you looking for income kings with reliable returns? Here are seven blue-chip dividend stocks for reliable returns. 
Via InvestorPlace
Fresh on the Market: 3 Top Picks From the Renaissance IPO ETF
There have not been many successful IPOs in 2023, so finding stock picks from the Renaissance IPO ETF won’t be easy. 
Via InvestorPlace
Topics ETFs Initial Public Offering
Exposures Securities Market
Johnson & Johnson MedTech Acquires Laminar, Inc.
From Johnson & Johnson MedTech
Via Business Wire
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
The 7 Biggest Dividend Stocks in Warren Buffett’s Portfolio
Are you curious about those Warren Buffet dividend stocks he owns in his portfolio? This article has you covered on the most important names. 
Via InvestorPlace
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
2023's most anticipated IPOs weren't always the big winners
146 U.S. companies went public in 2023, down 16.09% from last year. Despite market ups and downs, the Renaissance index of IPOs is outperforming the S&P 500 
Via MarketBeat
Topics ETFs Initial Public Offering Stocks
Exposures Securities Market US Equities
Daily Wear Contact Lenses Market May See a Big Move: Major Giants Alcon, Hydron, Lagado Corporation, Metro Optics, Johnson & Johnson Vision Care
According to HTF Market Intelligence, the Global Daily Wear Contact Lenses Market Breakdown by Application (Corrective Lenses, Therapeutic Lenses, Cosmetic Lenses, Lifestyle-Oriented Lenses) by Type... 
Via SBWire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
2 Unstoppable Dividend Stocks Trading Near 52-Week Lows to Buy Now
With clear advantages over the competition, these divided payers could deliver market-beating gains to patient investors. 
Via The Motley Fool
Google Alum's Biotech Startup Cradle Raises $24M To Boost AI-Powered Protein Design And Engineering
Dutch biotech startup Cradle has raised $24 million in Series A funding as it looks to boost its protein design and engineering process. 
Via Benzinga
3 Robotics Stocks That Could Be Multibaggers in the Making
These robotics stocks all deserve a place in your portfolio. Each company has unique value catalysts which make them worthy of consideration. 
Via InvestorPlace
The Shocking Stock That Warren Buffet Just Bought (and 2 He Sold)
The Oracle of Omaha buys a lot of different companies but the one stock that Warren Buffet just bought may surprise you. 
Via InvestorPlace
5 Stocks You Can Confidently Invest $500 In Right Now
These companies could significantly grow your investment over the long haul. 
Via The Motley Fool
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
These companies offer low-risk growth and income at a value price. 
Via The Motley Fool
Johnson & Johnson and Intuitive Surgical Might Become Ozempic's Next Victims. Are They Still Worth Buying?
With retailers worrying about Ozempic's impact, healthcare stocks could be next. 
Via The Motley Fool
Warren Buffett-Led Berkshire Hathaway Sells Its Entire Procter & Gamble Stake. Should You?
Procter & Gamble has proven it can justify repeated price hikes without overly damaging sales volume. 
Via The Motley Fool
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
Global Heart Failure Drugs Market Breakdown by Application (Reduced Ejection Fraction, Preserved Ejection Fraction) by Type (ACE inhibitors, Beta Blockers, Diuretics, Sacubitril Valsartan, Others) by... 
Via SBWire
3 Dividend Stocks You Can Safely Hold for Decades
Investors can confidently buy these income stocks for the long term. 
Via The Motley Fool
Skin Tightening Products Market to Witness Massive Growth by 2029 : L'Oréal, Johnson & Johnson, Amway
Stay up to date with Skin Tightening Products Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.